inclusion criteria: 1. participants ≥18 years of age (or the minimum country-specific age of consent if \>18) at the time of signing the informed consent/assent form. 2. initial positive sars-cov-2 tested by rt-pcr or rapid antigen test within 5 days (120 h) prior to the first dose of study drug collected from any respiratory tract specimen (e.g., oropharyngeal, np or nasal swab, or saliva). 3. initial onset of signs/symptoms attributable to covid-19 within 3 days prior to the day of the first dose of study drug. the onset time of symptoms was defined as the time when body temperature first rose; or the onset of any of these covid-19 symptoms. 4. at least one of the following symptoms of covid-19 present within 24 hours prior to the first dose of study drug and meeting severity. 5. has mild or moderate covid-19. 6. participants agree to take highly effective contraceptive measures from signing the informed consent to at least 1 month after the last dose of study intervention. 7. participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 8. willing and able to provide written informed consent, or with a legal representative who can provide informed consent.

inclusion criteria: 1. participants ≥18 years of age (or the minimum country-specific age of consent if \>18) at the time of signing the informed consent/assent form. 2. initial positive sars-cov-2 tested by rt-pcr or rapid antigen test within 5 days (120 h) prior to the first dose of study drug collected from any respiratory tract specimen (e.g., oropharyngeal, np or nasal swab, or saliva). 3. initial onset of signs/symptoms attributable to covid-19 within 3 days prior to the day of the first dose of study drug. the onset time of symptoms was defined as the time when body temperature first rose; or the onset of any of these covid-19 symptoms. 4. at least one of the following symptoms of covid-19 present within 24 hours prior to the first dose of study drug and meeting severity. 5. has mild or moderate covid-19. 6. participants agree to take highly effective contraceptive measures from signing the informed consent to at least 1 month after the last dose of study intervention. 7. participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 8. willing and able to provide written informed consent, or with a legal representative who can provide informed consent.

inclusion criteria: participants ≥18 years of age (or the minimum country-specific age of consent if >18) at the time of signing the informed consent/assent form. initial positive sars-cov-2 tested by rt-pcr or rapid antigen test within 5 days (120 h) prior to the first dose of study drug collected from any respiratory tract specimen (e.g., oropharyngeal, np or nasal swab, or saliva). initial onset of signs/symptoms attributable to covid-19 within 3 days prior to the day of the first dose of study drug. the onset time of symptoms was defined as the time when body temperature first rose; or the onset of any of these covid-19 symptoms. at least one of the following symptoms of covid-19 present within 24 hours prior to the first dose of study drug and meeting severity. has mild or moderate covid-19. participants agree to take highly effective contraceptive measures from signing the informed consent to at least 1 month after the last dose of study intervention. participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. willing and able to provide written informed consent, or with a legal representative who can provide informed consent.

inclusion criteria: participants ≥18 years of age (or the minimum country-specific age of consent if >18) at the time of signing the informed consent/assent form. initial positive sars-cov-2 tested by rt-pcr or rapid antigen test within 5 days (120 h) prior to the first dose of study drug collected from any respiratory tract specimen (e.g., oropharyngeal, np or nasal swab, or saliva). initial onset of signs/symptoms attributable to covid-19 within 3 days prior to the day of the first dose of study drug. the onset time of symptoms was defined as the time when body temperature first rose; or the onset of any of these covid-19 symptoms. at least one of the following symptoms of covid-19 present within 24 hours prior to the first dose of study drug and meeting severity. has mild or moderate covid-19. participants agree to take highly effective contraceptive measures from signing the informed consent to at least 1 month after the last dose of study intervention. participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. willing and able to provide written informed consent, or with a legal representative who can provide informed consent.

inclusion criteria: 1. participants ≥18 years of age 2.initial positive severe acute respiratory syndrome coronavirus 2(sars-cov-2)tested by reverse transcription-polymerase chain reaction(rt-pcr) or rapid antigen test within protocol specified time prior to the first dose of study drug collected from any respiratory tract specimen 3.with signs/symptoms attributable to covid-19 prior to the day of the first dose of study drug. 4. at least one of the following symptoms of covid-19 present within 24 hours prior to the first dose of study drug and meeting severity. 5. has mild or moderate covid-19. 6. participants agree to take highly effective contraceptive measures from signing the informed consent to at least 1 month after the last dose of study intervention. 7. participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 8. willing and able to provide written informed consent, or with a legal representative who can provide informed consent.

inclusion criteria: 1. participants ≥18 years of age 2.initial positive severe acute respiratory syndrome coronavirus 2(sars-cov-2)tested by reverse transcription-polymerase chain reaction(rt-pcr) or rapid antigen test within protocol specified time prior to the first dose of study drug collected from any respiratory tract specimen 3.with signs/symptoms attributable to covid-19 prior to the day of the first dose of study drug. 4. at least one of the following symptoms of covid-19 present within 24 hours prior to the first dose of study drug and meeting severity. 5. has mild or moderate covid-19. 6. participants agree to take highly effective contraceptive measures from signing the informed consent to at least 1 month after the last dose of study intervention. 7. participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 8. willing and able to provide written informed consent, or with a legal representative who can provide informed consent.